Kala Pharmaceuticals, Inc. (KALA)

NASDAQ: KALA · IEX Real-Time Price · USD
10.34
-0.35 (-3.23%)
At close: Sep 22, 2023, 4:00 PM
10.60
+0.26 (2.47%)
Pre-market: Sep 25, 2023, 7:35 AM EDT
-3.23%
Market Cap 26.30M
Revenue (ttm) 420,000
Net Income (ttm) -8.64M
Shares Out 2.54M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,863
Open 10.59
Previous Close 10.69
Day's Range 10.29 - 10.82
52-Week Range 3.54 - 56.72
Beta -1.50
Analysts Strong Buy
Price Target 24.00 (+132.01%)
Earnings Date Nov 7, 2023

About KALA

KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical d... [Read more]

Sector Healthcare
IPO Date Jul 20, 2017
Employees 34
Stock Exchange NASDAQ
Ticker Symbol KALA
Full Company Profile

Financial Performance

In 2022, KALA's revenue was $3.89 million, a decrease of -65.37% compared to the previous year's $11.24 million. Losses were -$44.82 million, -68.57% less than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for KALA stock is "Strong Buy" and the 12-month stock price forecast is $24.0.

Price Target
$24.0
(132.01% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside...

4 days ago - GlobeNewsWire

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative...

20 days ago - GlobeNewsWire

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio, Inc., a wholly owned subsidiary of KALA, awarde...

7 weeks ago - GlobeNewsWire

KALA BIO to Participate in Upcoming Investor Conferences in August

ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

7 weeks ago - GlobeNewsWire

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement aw...

2 months ago - GlobeNewsWire

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...

4 months ago - GlobeNewsWire

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 --...

4 months ago - GlobeNewsWire

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

MENLO PARK, Calif. and ARLINGTON, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development ...

5 months ago - GlobeNewsWire

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

--No safety issues identified in Cohort 1 -- -- Now proceeding to Cohort 2 to evaluate the safety and efficacy of two doses of KPI-012 in a multicenter, randomized, double-masked, vehicle-controlled t...

6 months ago - GlobeNewsWire

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

ARLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization o...

7 months ago - GlobeNewsWire

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

-- Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line data targeted for 1Q 2024 -- -- Closed $31.0 million private placement financing, extending cash runway...

7 months ago - GlobeNewsWire

Kala Pharmaceuticals Up 400% In The Past Month, What's Next?

Kala pharmaceuticals underwent a massive rally over the past few days, and by all indications, the stock price is now headed toward a bottom.

9 months ago - MarketBeat

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Shares of Kala Pharmaceuticals Inc. KALA, +39.53% have rocketed higher in for three-straight sessions, toward a more-than 8-fold gain, since the biopharmaceutical company announced positive news regar...

9 months ago - Market Watch

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Kala Pharmaceuticals Inc KALA shares are trading higher Thursday. The stock appears to be moving on continued momentum after the company on Wednesday announced FDA acceptance of an investigational new...

9 months ago - Benzinga

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Shares of Kala Pharmaceuticals Inc. KALA, +1.03% shot up 45.7% in premarket trading Wednesday, after the biopharmaceutical company said the Food and Drug Administration accepted its investigational ne...

9 months ago - Market Watch

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 --  -- Received remaining $25 million investment under previously announced private placement financing -- ARLINGTON...

9 months ago - GlobeNewsWire

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 -- -- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing,...

10 months ago - GlobeNewsWire

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

ARLINGTON, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...

10 months ago - GlobeNewsWire

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

-- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 -- -- Ended Quarter with $52.4 million in Cash; Sufficie...

11 months ago - GlobeNewsWire

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, developme...

11 months ago - GlobeNewsWire

Kala Pharmaceuticals Announces Reverse Stock Split

Common Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022 Common Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022

1 year ago - GlobeNewsWire

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

ARLINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization o...

1 year ago - GlobeNewsWire

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ARLINGTON, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as an inducement awa...

1 year ago - GlobeNewsWire

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, developmen...

1 year ago - GlobeNewsWire

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 -- -- Received $60M Upfront Payment from Sale of EYSUVIS® an...

1 year ago - GlobeNewsWire